Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
CREST trial: what clinicians have said so far
A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer
- NCT04165317 ↗
- Active, not recruiting
- Pfizer
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on CREST yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on CREST so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 5 posts on X, typically up to 22 once built |
The trial
ClinicalTrials.gov- Official title
- A Phase 3, Multinational, Randomized, Open-Label, Three Parallel-Arm Study of PF-06801591, an Anti-PD-1 Antibody, in Combination With Bacillus Calmette-Guerin (BCG Induction With or Without BCG Maintenance) Versus BCG (Induction and Maintenance) in Participants With High-Risk, BCG-Naïve Non-Muscle Invasive Bladder Cancer or PF-06801591 as a Single Agent in Participants With BCG-Unresponsive NMIBC
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Non-muscle Invasive Bladder Cancer
- Interventions
- PF-06801591; Bacillus Calmette-Guerin
- Arms
- PF-06801591 + BCG induction and maintenance · Experimental
- PF-06801591 + BCG induction only · Experimental
- BCG induction and maintenance · Active comparator
- BCG Unresponsive CIS · Experimental
- BCG Unresponsive NMIBC · Experimental
- Enrollment
- 1,068
- Primary outcomes
- Cohort A: Event Free Survival (EFS) as Assessed by the Investigator: Arm A Versus Arm C
- Sponsor
- Pfizer
- Start
- Dec 30, 2019
- Primary completion
- Dec 2, 2024
- Results posted
- Yes
- Registry record
- NCT04165317 · updated Oct 15, 2026
Publications
linked from the registry- Shore ND, Powles TB, Bedke J, Galsky MD, Redorta JP, Ku JH, Kretkowski M, Xylinas E, Alekseev B, Ye D, Guerrero-Ramos F, Briganti A, Kulkarni GS, Brinkmann J, Calella AM, Cesari R, Eccleston A, Michelon E, Vermette J, Wei C, Steinberg GD. Sasanlimab taken together with Bacillus Calmette-Guerin (BCG) compared with BCG alone in people with high-risk non-muscle invasive bladder cancer: a plain language summary. Future Oncol. 2026 Jun;22(13):1487-1499. doi: 10.1080/14796694.2026.2671256. Epub 2026 May 24. PubMed 42177753
- Shore ND, Powles TB, Bedke J, Galsky MD, Palou Redorta J, Ku JH, Kretkowski M, Xylinas E, Alekseev B, Ye D, Guerrero-Ramos F, Briganti A, Kulkarni GS, Brinkmann J, Calella AM, Cesari R, Eccleston A, Michelon E, Vermette J, Wei C, Steinberg GD. Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trial. Nat Med. 2025 Aug;31(8):2806-2814. doi: 10.1038/s41591-025-03738-z. Epub 2025 May 31. PubMed 40450141
- Steinberg GD, Shore ND, Redorta JP, Galsky MD, Bedke J, Ku JH, Kretkowski M, Hu H, Penkov K, Vermette JJ, Tarazi JC, Randall AE, Pierce KJ, Saltzstein D, Powles TB. CREST: phase III study of sasanlimab and Bacillus Calmette-Guerin for patients with Bacillus Calmette-Guerin-naive high-risk non-muscle-invasive bladder cancer. Future Oncol. 2024 May;20(14):891-901. doi: 10.2217/fon-2023-0271. Epub 2024 Jan 8. PubMed 38189180